Understanding the role of long-acting muscarinic antagonists in asthma treatment

Muiser, Susan; Gosens, Reinoud; Berge, M. van den; Kerstjens, H.A.M.

doi:10.1016/j.anai.2021.12.020

Cited by 15 publications

(9 citation statements)

References 40 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tiotropium is one of the muscarinic antagonists that binds M3 receptors widely expressed throughout airways, resulting in attenuation of bronchoconstriction caused by acetylcholine released from the vagal nerve. 17,18 Until now, muscarinic antagonists have mostly been used for COPD, not asthma, because direct bronchoconstriction by inflammatory substances such as leukotrienes was considered as more important pathophysiology in asthma rather than bronchoconstriction by increasing vagal tone. 15,19 The first publication of the "Global Strategy for Asthma Management and Prevention" report was in 1995.…”

Section: Discussionmentioning

confidence: 99%

Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

Shim

Jin

Kim

et al. 2022

World Allergy Organization Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

Shim

Jin

Kim

et al. 2022

World Allergy Organization Journal

View full text Add to dashboard Cite

“…Three LAMA molecules-Tiotropium (TIO), Glycopyrronium (GLY), and umeclidinium-have been studied as add-ons, each with slightly different action onsets and half-lives. GLY, in particular, acts slightly faster than TIO and umeclidinium may have similar properties [163].…”

Section: The Role Of Standard Therapy In Airway Remodeling (Lama)mentioning

confidence: 96%

The New Paradigm: The Role of Proteins and Triggers in the Evolution of Allergic Asthma

Baglivo,

Quaranta,

Dragonieri

et al. 2024

Preprint

View full text Add to dashboard Cite

Epithelial barrier damage plays a central role in the development and maintenance of allergic inflammation. The rise in airways epithelial barrier permeability alters the tissue homeostasis and allows the allergen and other external agents penetration. Different factors contribute to barrier impairment, such as eosinophilic infiltrate and allergens proteases action: the eosinophilic cationic proteins and the allergens' proteolytic activity have a central role in contributing to epithelial damage. In the airways, the allergens proteases degrade the epithelial junctional proteins allowing the allergen penetration and the uptake by dendritic cells. The increase in allergen-immune system interactions induce the release of the alarmins and the activation of type 2 inflammatory pathways causing, or worsening, the main symptoms at skin, bowel and respiratory levels. We aim to highlight the molecular mechanisms underlying allergenic proteases-induced epithelial barrier damage and the role of immune response in allergic asthma onset, maintenance and progression. We further will explore clinical and radiological potential biomarkers of airways remodeling in allergic asthma patients.

show abstract

“…Three LAMA molecules—Tiotropium (TIO), Glycopyrronium (GLY), and umeclidinium—have been studied as add-ons, each with slightly different action onsets and half-lives. GLY, in particular, acts slightly faster than TIO, and umeclidinium may have similar properties [ 162 ].…”

Section: Relevant Therapeutic Options and New Potential Therapeutic T...mentioning

confidence: 99%

The New Paradigm: The Role of Proteins and Triggers in the Evolution of Allergic Asthma

Baglivo,

Quaranta,

Dragonieri

et al. 2024

IJMS

View full text Add to dashboard Cite

Epithelial barrier damage plays a central role in the development and maintenance of allergic inflammation. Rises in the epithelial barrier permeability of airways alter tissue homeostasis and allow the penetration of allergens and other external agents. Different factors contribute to barrier impairment, such as eosinophilic infiltration and allergen protease action—eosinophilic cationic proteins’ effects and allergens’ proteolytic activity both contribute significantly to epithelial damage. In the airways, allergen proteases degrade the epithelial junctional proteins, allowing allergen penetration and its uptake by dendritic cells. This increase in allergen–immune system interaction induces the release of alarmins and the activation of type 2 inflammatory pathways, causing or worsening the main symptoms at the skin, bowel, and respiratory levels. We aim to highlight the molecular mechanisms underlying allergenic protease-induced epithelial barrier damage and the role of immune response in allergic asthma onset, maintenance, and progression. Moreover, we will explore potential clinical and radiological biomarkers of airway remodeling in allergic asthma patients.

show abstract

Understanding the role of long-acting muscarinic antagonists in asthma treatment

Cited by 15 publications

References 40 publications

Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

The New Paradigm: The Role of Proteins and Triggers in the Evolution of Allergic Asthma

The New Paradigm: The Role of Proteins and Triggers in the Evolution of Allergic Asthma

Contact Info

Product

Resources

About